News
Molecular Imaging News
April 27, 2006
New Funding Initiatives from National Institutes of Health
Cancer Imaging Program, NCI
The National Institutes of Health (NIH) recently issued a number of funding opportunity announcements of interest to the nuclear medicine community.
- Radionuclide Decorporation Agents For Radiation/Nuclear Emergencies: Project Bioshield
The National Institute of Allergy and Infectious Diseases is sponsoring this opportunity to accelerate the development of safe and effective products to remove radionuclides from the body (decorporation) following nuclear contamination from any source. Specifically, candidate products will demonstrate an increase in efficiency and rate of radionuclide elimination from the body after contamination due to ingestion, inhalation, or transdermal absorption. For more information, see: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-06-030.html. Applications are due May 15. - Quick-Trials for Imaging and Image-Guided Interventions: Exploratory Grants
In this funding opportunity, the National Cancer Institute (NCI) will focus on the following areas of research: 1) phase I or II clinical trials of novel imaging-agents to ensure their safety and efficacy so that further evaluations of the clinical potentials of these agents can proceed; 2) feasibility studies in image-guided intervention, to establish treatment parameters and early therapeutic efficacy for these methods; and/or 3) clinical feasibility or “proof-of-principle” studies or clinical trials to demonstrate potential efficacy of promising discoveries in imaging or image-guided therapy methodologies or technologies, such as, but not limited to, image acquisition devices or systems, software for image-acquisition, image processing, image-guided therapy, contrast kinetic modeling, or 3-D reconstruction and quantitative tools. For more information see: http://grants.nih.gov/grants/guide/pa-files/PAR-06-293.html. Applications receipt dates are: August 9, 2006; December 9, 2006; April 9, 2007; August 9, 2007; December 9, 2007; April 9, 2008. - Understanding the Effects of Emerging Cellular, Molecular, and Genomic Technologies on Cancer Health Care Delivery
NCI invites applications for health services research addressing utilization of cellular, molecular, and genetic or genomic (CMG) technologies in cancer care. The studies will assess CMG technologies in relation to: quality of care; organizational barriers and change factors in utilization; cost and cost-effectiveness; disparities in access and efficacy; monitoring of cross-sectional patterns of care and time trends; impact on existing standards of care; and influence on cancer outcomes such as incidence, progression, mortality, survival, and quality of life. This funding opportunity specifically encourages research on commercially available CMG clinical tools already in use, as well as experimental tools in the later stages of development and/or in the regulatory approval pipeline. For more information see: http://grants.nih.gov/grants/guide/pa-files/PA-06-280.html and http://grants.nih.gov/grants/guide/pa-files/PA-06-281.html. - Exploratory Studies in Cancer Detection, Diagnosis, and Prognosis
The objective of this funding opportunity from NCI is to encourage grant applications for exploratory grants from individuals who are interested in testing new ideas that may advance progress in cancer detection, diagnosis, and prognosis. Imaging studies are not intended to be funded under this initiative. For imaging initiatives, call the Cancer Imaging Program staff. For more information see: http://grants.nih.gov/grants/guide/pa-files/PA-06-299.html. - Imaging—Science Track Award for Research Transition
The National Institute on Drug Abuse intends to facilitate the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs. For more information see: http://grants.nih.gov/grants/guide/pa-files/PAR-06-311.html. - Neurotechnology Research, Development, and Enhancement
This multi-institute funding opportunity is designed to encourage submission of new exploratory/developmental (R21) grant applications to research and develop innovative technologies, methodologies, or instrumentation for basic or clinical studies of the brain or behavior in human or non-human animals. Also solicited are applications for support to research, develop, and significantly enhance existing technologies that are important to understanding the brain or behavior. For more information see: http://grants.nih.gov/grants/guide/pa-files/PA-06-278.html and http://grants.nih.gov/grants/guide/pa-files/PA-06-279.html. - CIP DCIDE Program
The Cancer Imaging Program (imaging.cancer.gov)of the NCI is requesting submissions for its Development of Clinical Imaging Drugs and Enhancers (DCIDE) initiative. The goal is the rapid movement of promising, novel cancer imaging enhancers or molecular probes from the laboratory to proof-of-principle clinical trials. For details see: http://imaging.cancer.gov/programsandresources/specializedinitiatives/dcide.
